The impact of drug shortages in Japan, including of essential products, is being considered as part of government-level discussions to consider the appropriateness of the current reimbursement pricing system. Amid rising production costs and wider global challenges, some experts in the industry are now asking for price increases.

Teva announced the appointment of former Sandoz CEO Richard Francis as its next leader as Kare Schultz steps down.

Sawai’s Q1 momentum spread into its overall first half financial results, with setbacks and risks in its dominant Japanese business and greener shoots for its formerly spluttering Upsher-Smith operation in the US.

Sawai’s Upsher-Smith business in the US has announced a pair of deals that will see the firm expand an existing partnership with Appco for a “near-term generic product opportunity” as well as divesting two “dormant” ANDAs in favor of a focus on more immediate assets.